Welcome to our dedicated page for Evogene Ltd. news (Ticker: $EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evogene Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evogene Ltd.'s position in the market.
Biomica , a subsidiary of Evogene, released promising preliminary data from a Phase 1 trial of BMC128, a microbiome-based immuno-oncology candidate, in combination with nivolumab. This trial involves patients with refractory NSCLC, melanoma, or RCC. Key findings include an exceptional safety profile with no major safety events, 72% of refractory cases showing positive clinical signals, and 64% of patients demonstrating stable disease. Additionally, 55% of patients showed sustained clinical benefits beyond 16 weeks, with some exceeding 80 weeks. The data will be presented at the 2024 ASCO annual meeting.
Evogene (NASDAQ: EVGN) reported its Q1 2024 financial results, showing significant improvements. Revenues increased to $4.2M from $0.6M in Q1 2023, driven by Lavie Bio's licensing agreement with Corteva and AgPlenus's collaboration with Bayer. Net loss reduced to $3.8M from $7.0M in the previous year. Projected 2024 cash usage is expected to decrease by 36% to $8.0M. Ceasing Canonic operations will save $1.5M annually. Key developments include Biomica's Phase 1 trial data presentation, Lavie Bio's new collaborations, and AgPlenus's agreement with Bayer.
Casterra Ag has signed new agreements with seed producers in Africa to meet the growing demand for its elite castor seeds. These agreements will support the production of approximately 500 tons of additional seeds, ensuring the fulfillment of orders received in 2023 by the end of 2024.
Together with previous agreements for 400 tons of seeds announced in February, this move positions Casterra to fulfill both current and future demands. The company leverages Evogene's 'GeneRator AI' technology to develop high-yielding, high-oil castor seeds, important for sustainable biofuel production.
Casterra aims to establish a reliable seed production infrastructure, mitigating production risks and reinforcing its market position in the biofuel industry.
Evogene (Nasdaq: EVGN) announces the release of its first quarter 2024 financial results on May 23, 2024. A conference call is scheduled for 9:00 AM ET to discuss the results. Register in advance to join the call.